Scientists Discover Rare New Human Blood Group 'JAMA' Recognized as 49th System
_1421836153.jpg)
Marking an extraordinary breakthrough in hematology and transfusion medicine, an international team of British and Israeli researchers has identified a completely new human blood group system named JAMA, officially recognized by the International Society of Blood Transfusion (ISBT) as the world's 49th distinct blood group classification. While human blood functions far beyond oxygen transportation by delivering essential nutrients, hormones, and cellular defenses throughout the body, clinical blood typing has historically centered on standard classifications like A, B, AB, and O alongside the Rh factor. The formal identification of the JAMA system demonstrates the immense biological complexity governing red blood cell surfaces and provides life-saving insights for global blood banks and specialized critical care units managing rare antibody incompatibilities during emergency surgical procedures.
Origin of Discovery: Israeli Siblings and the F11R Genetic Mutation
The medical discovery originated when clinicians investigated the blood profile of an Israeli female patient and her brother during routine cross-matching diagnostics. Laboratory tests revealed that the woman’s plasma contained an unidentified, highly potent antibody that aggressively reacted against red blood cells from nearly all standard human donor samples, yet displayed zero adverse reaction when cross-matched against her own cells or those of her brother. Intrigued by an antibody that failed to match any documented antigen across the known 48 blood systems, researchers initiated deep genomic sequencing of both siblings. The DNA analysis uncovered a rare genetic mutation in the F11R gene, which is responsible for synthesizing a cell-adhesion surface protein designated as JAM-A (Junctional Adhesion Molecule-A). While the JAM-A protein is universally present on the red blood cell membranes of the overwhelming majority of the human population, the siblings harbored a rare null variant lacking this surface antigen entirely, leading their immune systems to treat conventional red blood cells as foreign entities and generate targeted antibodies against them.
Clinical Impact: Eliminating Transfusion Risks for Patients with Ultra-Rare Antigens
Rather than functioning as an everyday standalone category like A or O, JAMA operates as an intricate, distinct antigen-antibody system essential for precision cross-matching. In clinical environments, administering regular donor blood that carries the ubiquitous JAM-A surface antigen to an individual lacking it can trigger catastrophic acute hemolytic transfusion reactions as circulating recipient antibodies attack donor red cells. The formal codification of JAMA as the 49th blood group system equips transfusion medicine specialists, donor registries, and trauma centers with the molecular diagnostic screening tools needed to accurately identify compatible donors for rare-antigen patients. By resolving previously unexplained cross-match failures, this discovery prevents potentially fatal post-transfusion immune reactions and establishes a new benchmark for personalized patient treatment worldwide.
_954768021_351x234.jpg)
_1053719450_351x234.jpg)
_1711925682_351x234.jpg)
_1421836153_351x234.jpg)